Novo co-led the series C round with Longitude Capital and Checkmate will use the cash to advance clinical development of its lead asset, which is targeting melanoma.
US-based cancer therapy developer Checkmate Pharmaceuticals completed an $85m series C round on Wednesday co-led by pharmaceutical firm Novo and venture capital firm Longitude Capital.
The round included BrightEdge and F-Prime Capital, on behalf of charity American Cancer Society and financial services group Fidelity, as well as Medicxi, Omega Funds, Clough Capital Partners, Sectoral Asset Management, Sofinnova Investments, VenBio Partners and Decheng Capital.
Checkmate is working on cancer treatments that help the body’s immune system overcome cancer cells’ ability to…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
